NFE2L2 and breast carcinoma: Additionally, it has been demonstrated that luteolin lowers nuclear factor erythroid 2-related factor 2 (Nrf2)-driven activation and prevents STAT3 from making human breast cancer MDA-MB-231 cells more vulnerable to the drugs doxorubicin and paclitaxel [115].